Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (191-200 of 266) with videos related to

Pageof 27
Sort By:
The Oncologist|January 14, 2018
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)Barbara Nuñez-Valdovinos, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, et al.
European Urology|November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 TrialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
European Urology|November 9, 2019
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancerAlfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al.
The Lancet. Oncology|April 9, 2017
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trialJesus García-Donas, Albert Font, Begoña Pérez-Valderrama, et al.
BMC Cancer|December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerHelmut Friess, Jan M Langrehr, Helmut Oettle, et al.
British Journal of Cancer|May 7, 2025
A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR studyÁlvaro Pinto-Marín, Lucía Trilla-Fuertes, Jesús Miranda Poma, et al.
Cancer Medicine|November 13, 2019
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)Ben Tran, Jose M Ruiz-Morales, Enrique Gonzalez-Billalabeitia, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2022
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trialMiguel A Climent, Albert Font, Ignacio Durán, et al.
European Urology Focus|July 30, 2017
A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)Jesús García-Donas, Luis Angel Leon, Emilio Esteban, et al.
Pageof 27

Showing results (191-200 of 266) with videos related to

Sort By:
Pageof 27
The Oncologist|January 14, 2018
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)Barbara Nuñez-Valdovinos, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, et al.
European Urology|November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 TrialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
European Urology|November 9, 2019
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancerAlfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al.
The Lancet. Oncology|April 9, 2017
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trialJesus García-Donas, Albert Font, Begoña Pérez-Valderrama, et al.
BMC Cancer|December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerHelmut Friess, Jan M Langrehr, Helmut Oettle, et al.
British Journal of Cancer|May 7, 2025
A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR studyÁlvaro Pinto-Marín, Lucía Trilla-Fuertes, Jesús Miranda Poma, et al.
Cancer Medicine|November 13, 2019
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)Ben Tran, Jose M Ruiz-Morales, Enrique Gonzalez-Billalabeitia, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2022
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trialMiguel A Climent, Albert Font, Ignacio Durán, et al.
European Urology Focus|July 30, 2017
A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)Jesús García-Donas, Luis Angel Leon, Emilio Esteban, et al.
Pageof 27